title: A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors.
abstract: Although the majority of papillary thyroid cancer (PTC) is indolent, a subset of PTC behaves aggressively despite the best available treatment. A major clinical challenge is to reliably distinguish early on between those patients who need aggressive treatment from those who do not. Using a large cohort of PTC samples obtained from The Cancer Genome Atlas (TCGA), we analyzed the association between disease progression and multiple forms of genomic data, such as transcriptome, somatic mutations, and somatic copy number alterations, and found that genes related to FOXM1 signaling pathway were significantly associated with PTC progression. Integrative genomic modeling was performed, controlling for demographic and clinical characteristics, which included patient age, gender, TNM stages, histological subtypes, and history of other malignancy, using a leave-one-out elastic net model and 10-fold cross validation. For each subject, the model from the remaining subjects was used to determine the risk index, defined as a linear combination of the clinical and genomic variables from the elastic net model, and the stability of the risk index distribution was assessed through 2,000 bootstrap resampling. We developed a novel approach to combine genomic alterations and patient-related clinical factors that delineates the subset of patients who have more aggressive disease from those whose tumors are indolent and likely will require less aggressive treatment and surveillance (p = 4.62 × 10-10, log-rank test). Our results suggest that risk index modeling that combines genomic alterations with current staging systems provides an opportunity for more effective anticipation of disease prognosis and therefore enhanced precision management of PTC.
authors.affiliation: Department of Surgery, Duke University Medical Center, Durham, NC 27710 USA.|Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710 USA.
authors.forename: Qing
authors.initials: Q
authors.lastname: Cheng
authors.affiliation: Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710 USA.
authors.forename: Xuechan
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Surgery, Duke University Medical Center, Durham, NC 27710 USA.
authors.forename: Chaitanya R
authors.initials: CR
authors.lastname: Acharya
authors.affiliation: Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC 27710 USA.|Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710 USA.
authors.forename: Terry
authors.initials: T
authors.lastname: Hyslop
authors.affiliation: Department of Surgery, Duke University Medical Center, Durham, NC 27710 USA.|Department of Medicine, Duke University Medical Center, Durham, NC 27710 USA.|Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710 USA.
authors.forename: Julie Ann
authors.initials: JA
authors.lastname: Sosa
mesh_terms: D002277:Carcinoma / Q000235:genetics* / Q000473:pathology*; D002291:Carcinoma, Papillary; D018450:Disease Progression; D018572:Disease-Free Survival; D023281:Genomics; D006801:Humans; D011379:Prognosis; D012307:Risk Factors; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000235:genetics* / Q000473:pathology*
keywords: clinical and pathologic factors; disease progression; genomic alterations; papillary thyroid cancer; risk index model